Abstract
Systemic arterial hypertension (SAH) is a risk factor for 9.4 million deaths worldwide. In Brazil, HAS assigned an annual cost of about 1.5 billion to the Public Health System (PHS). The Pharmaceutical Care (PC) is able to avoid complications of hypertension and reduce health costs. The PC economic analysis in long-term showed that the net return on investment in this pharmaceutical pract…